TransMedics Group (NasdaqGM:TMDX) FY Conference Transcript

Summary of TransMedics Group FY Conference Call Company Overview - Company: TransMedics Group (NasdaqGM:TMDX) - Industry: Organ transplantation and medical devices Key Points OCS Kidney Program - The OCS Kidney program is expected to be the largest initiative by TransMedics, targeting tens of thousands of OCS runs in transplant cases [7][8] - Current post-transplant complication rates requiring dialysis (delayed graft function, DGF) are at 55%-60%, up from 20%-25% in 1998, indicating a significant clinical need [8][9] - Kidney utilization in the U.S. is at an all-time low of approximately 60%, down from 90%-92% in 1990, highlighting the need for improved preservation methods [9] - The OCS Kidney aims to reduce DGF by 50% and improve kidney donor utilization, with 9,000 donor kidneys not transplanted in 2025 due to prolonged ischemic time [9][10] - The OCS Kidney device is expected to be ready for clinical rollout by late 2026 or early 2027 [11] Technology and Market Dynamics - The OCS technology offers ischemia-free kidney transplants, which is a significant advancement over existing cold ischemic perfusion methods [15][16] - The complexity of the donor pool and the increase in donation after cardiac death (DCD) are contributing to the challenges in kidney transplantation [19] - The OCS Kidney program is expected to benefit both DBD (donation after brain death) and DCD kidneys, with financial efficiencies anticipated for CMS [20][21] Next-Gen OCS System - The next-gen OCS system will be smaller, with fewer parts, leading to reduced assembly costs and increased production efficiency [23] - Clinical assessments may be conducted remotely, reducing the need for on-site clinical specialists, which will improve operational leverage [24] Clinical Trials and Milestones - The design of the OCS Kidney has been presented at key conferences, with further milestones expected at the American Transplant Congress in June [25][26] - The clinical endpoints will focus on the incidence of DGF and the need for dialysis within the first 30 days post-transplant [33] Regulatory and Market Positioning - TransMedics is actively engaging with CMS and is well-positioned to adapt to changes in the U.S. Transplant Network, which aims to increase organ utilization [37][39] - The company has invested significantly in developing a national network for organ preservation and transplantation, emphasizing its unique position in the market [40][41] Growth and Revenue Outlook - The company anticipates continued growth from the OCS Liver franchise, with confidence in its technology's superiority over competitors [75] - Current revenue guidance for 2026 does not include contributions from the OCS Lung trial, allowing for potential upside as the trial progresses [51][53] International Expansion - TransMedics is expanding into international markets, particularly in Europe, with Italy expected to be fully operational by the end of 2026 [76][78] - Additional European countries such as the Netherlands, Belgium, France, UK, and Switzerland are being targeted for future expansion [78] Additional Insights - The company emphasizes its commitment to supporting OPOs (Organ Procurement Organizations) to improve organ transplant rates, as its business model relies on successful transplants [63] - The OCS technology is positioned as a critical tool in addressing the challenges of organ transplantation, with ongoing efforts to enhance its adoption and effectiveness in the market [75]